SYDNEY, AUSTRALIA: Anagenics Limited (AN1) has appointed Scott Greasley as CEO and Managing Director of the company, effective 1 April 2023.
Scott Greasley has been an Executive Director of Anagenics since 8 July 2022 and full-time employee since 1 September 2022, focusing on M&A, business development and working with management on the AN1 transformation.
Following Anagenics streamlining, cost base reset and balance sheet strengthening over the past 12 months, Scott will lead Anagenics next phase, with a focus on profitable revenue growth and accretive M&A.
Scott has over 15 years’ success building and integrating market-leading, profitable global consumer businesses, most recently as Head of Greater China and Emerging Markets for Boardriders Group and prior to that with the Billabong Group in Singapore and Australia, operating across all verticals of the business.
Matthew Dudek has been appointed Chief Financial & Governance Officer of Anagenics, having been Acting CEO since 28 February 2022 and Group Financial Controller since 2020. The Board would like to thank Matthew for his efforts in the role and bringing stability to the business for its next phase which he will be a key part of in partnership with Scott.
Anagenics Limited (ASX: AN1) is a health and beauty-tech business growing shareholder value through the global distribution and sales of its proprietary and licensed brands of differentiated, clinically validated anti-aging solutions.
BLC Cosmetics Pty Ltd is Anagenics’ wholly owned subsidiary focused on sales and distribution of leading Australian and international brands of cosmetic and wellness products.
Advangen Pty Ltd is Anagenics’ wholly owned subsidiary engaged in the development and sale of proprietary first in class, best in class, clinically validated products for hair, skin and body.